JP2022547234A5 - - Google Patents
Info
- Publication number
- JP2022547234A5 JP2022547234A5 JP2022539991A JP2022539991A JP2022547234A5 JP 2022547234 A5 JP2022547234 A5 JP 2022547234A5 JP 2022539991 A JP2022539991 A JP 2022539991A JP 2022539991 A JP2022539991 A JP 2022539991A JP 2022547234 A5 JP2022547234 A5 JP 2022547234A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- composition according
- cancer
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893316P | 2019-08-29 | 2019-08-29 | |
| US62/893,316 | 2019-08-29 | ||
| PCT/JP2020/034615 WO2021040056A1 (en) | 2019-08-29 | 2020-08-27 | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547234A JP2022547234A (ja) | 2022-11-10 |
| JP2022547234A5 true JP2022547234A5 (enExample) | 2023-08-16 |
Family
ID=73038366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539991A Pending JP2022547234A (ja) | 2019-08-29 | 2020-08-27 | 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220290179A1 (enExample) |
| EP (1) | EP4021471A1 (enExample) |
| JP (1) | JP2022547234A (enExample) |
| KR (1) | KR20220054819A (enExample) |
| CN (1) | CN114585376A (enExample) |
| AU (1) | AU2020337690A1 (enExample) |
| BR (1) | BR112022001881A2 (enExample) |
| CA (1) | CA3151667A1 (enExample) |
| CO (1) | CO2022003004A2 (enExample) |
| IL (1) | IL290819A (enExample) |
| MX (1) | MX2022002417A (enExample) |
| PH (1) | PH12022550240A1 (enExample) |
| WO (1) | WO2021040056A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119677861A (zh) * | 2022-06-10 | 2025-03-21 | 特兰斯吉恩股份有限公司 | 表达白介素-12的重组病毒 |
| CN119923267A (zh) * | 2022-07-27 | 2025-05-02 | 阿斯利康(瑞典)有限公司 | 表达白介素-12的重组病毒与pd-1/pd-l1抑制剂的组合 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| DK1133316T3 (da) * | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| ATE420160T1 (de) | 2003-06-18 | 2009-01-15 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| WO2005007824A2 (en) | 2003-07-08 | 2005-01-27 | Arizona Board Of Regents | Mutants of vaccinia virus as oncolytic agents |
| EP1518932A1 (en) | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| MX2008016036A (es) | 2006-06-20 | 2009-04-07 | Transgene Sa | Vacuna viral recombinante. |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| CN110527670A (zh) | 2013-11-21 | 2019-12-03 | 国立大学法人鸟取大学 | 丝裂原活化蛋白激酶依赖性重组痘苗病毒(md-rvv)及其应用 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| GB201405834D0 (en) | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| WO2015159420A1 (ja) | 2014-04-18 | 2015-10-22 | 株式会社エムジーモールド | 多層シートからなる中空体の製造方法および製造システム |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| KR102507483B1 (ko) * | 2014-12-01 | 2023-03-07 | 트랜스진 | 안정한 액체 백시니아 바이러스 제제 |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| PT3356413T (pt) | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| WO2017209053A1 (ja) | 2016-05-30 | 2017-12-07 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
| KR20190112263A (ko) * | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| WO2018234506A2 (en) * | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
-
2020
- 2020-08-27 PH PH1/2022/550240A patent/PH12022550240A1/en unknown
- 2020-08-27 MX MX2022002417A patent/MX2022002417A/es unknown
- 2020-08-27 JP JP2022539991A patent/JP2022547234A/ja active Pending
- 2020-08-27 KR KR1020227009370A patent/KR20220054819A/ko not_active Withdrawn
- 2020-08-27 US US17/632,686 patent/US20220290179A1/en not_active Abandoned
- 2020-08-27 BR BR112022001881A patent/BR112022001881A2/pt unknown
- 2020-08-27 CN CN202080073316.7A patent/CN114585376A/zh active Pending
- 2020-08-27 WO PCT/JP2020/034615 patent/WO2021040056A1/en not_active Ceased
- 2020-08-27 EP EP20799848.5A patent/EP4021471A1/en not_active Withdrawn
- 2020-08-27 AU AU2020337690A patent/AU2020337690A1/en not_active Abandoned
- 2020-08-27 CA CA3151667A patent/CA3151667A1/en active Pending
-
2022
- 2022-02-22 IL IL290819A patent/IL290819A/en unknown
- 2022-03-15 CO CONC2022/0003004A patent/CO2022003004A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Edeline et al. | CAR-T cells and BiTEs in solid tumors: challenges and perspectives | |
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| AU2019305857B2 (en) | Drug combination of quinoline derivative and antibody | |
| US20240066040A1 (en) | Ep4 inhibitors and use thereof | |
| BR112020024235A2 (pt) | proteínas de ligação multiespecíficas e aprimoramento das mesmas | |
| BR112020003050A2 (pt) | proteínas de ligação a nkg2d, cd16, e egfr, hla-e, ccr4 ou pd-l1 | |
| JP2023089171A (ja) | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 | |
| BR112020001266A2 (pt) | anticorpos anti-ctla-4 e usos dos mesmos | |
| KR20230165876A (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP2018509175A (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| KR20220007593A (ko) | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| JP2016528195A5 (enExample) | ||
| BR112019010878A2 (pt) | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| WO2020067085A1 (ja) | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 | |
| KR20240038991A (ko) | 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합 | |
| CN114746116A (zh) | 用于免疫疗法的组合物和方法 | |
| JP2022547234A5 (enExample) | ||
| TW202104263A (zh) | 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案 | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| WO2025082449A1 (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| US20250282871A1 (en) | Pharmaceutical combination and use thereof | |
| CN119868536A (zh) | 用于治疗癌症的组合疗法 | |
| CN117693350A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| CN110812485A (zh) | 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途 |